Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 171-176

  Weiss, L ^a   Melchardt, T ^a   Habringer, S ^a   Boekstegers, A ^a   Hufnagl, C ^a   Neureiter, D ^a   Hopfinger, G ^a   Greil, R ^a   Egle, A ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Body mass index; Diffuse large B cell lymphoma; Obesity; Prognosis; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B SYMPTOM; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE SCORE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBESITY; OVERALL SURVIVAL; PATIENT CODING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOCIAL STATUS; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREND STUDY; VERY ELDERLY;

BODY MASS INDEX; DIFFUSE LARGE B-CELL LYMPHOMA; OBESITY; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84905374454     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt481     Document Type: Article

References (26)

1. Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
2. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
3. Patel AV, Diver WR, Teras LR et al. Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 2013; 54: 1221-1227.
4. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567.
5. Cheymol G. Effects of obesity on pharmacokinetics-implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-231.
6. Jain R, Chung SM, Jain L et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011; 90: 77-89.
7. Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165: 1267-1273.
8. Pfeiler G, Konigsberg R, Fesl C et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29: 2653-2659.
9. Jones JA, Fayad LE, Elting LS et al. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010; 51: 1649-1657.
10. Navarro WH, Loberiza FR, Bajorunaite R et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 541-551.
11. Vogl DT, Wang T, Perez WS et al. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2011; 17: 1765-1774.
12. Hadjibabaie M, Tabeefar H, Alimoghaddam K et al. The relationship between body mass index and outcomes in leukemic patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Transplant 2012; 26: 149-155.
13. Nikolousis E, Nagra S, Paneesha S et al. Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Ann Hematol 2010; 89: 1141-1145.
14. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
15. Carson KR, Bartlett NL, McDonald JR et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large Bcell lymphoma. J Clin Oncol 2012; 30: 3217-3222.
16. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045.
17. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
18. WHO. Technical Report series 854. Physical status: the use and interpretation of anthropomorphy. Report of a WHO Expert Committee, 1995.
19. Fridrik MA, Petzer AL, Keil F et al. Non-pegylated liposomal encapsulated doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma (DLBCL). Final results of a randomized trial. Blood 2011; 118: 1149.
20. Grossschadl F, Stronegger WJ. Regional trends in obesity and overweight among Austrian adults between 1973 and 2007. Wien Klin Wochenschr 2012; 124: 363-369.
21. Carella AM, de Souza CA, Luminari S et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study. Leuk Lymphoma 2013; 54: 53-57.
22. Griggs JJ, Mangu PB, Anderson H et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2012; 30: 1553-1561.
23. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol 2005; 16: 1413-1424.
24. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-1327.
25. Jager U, Fridrik M, Zeitlinger M et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012; 97: 1431-1438.
26. Muller C, Murawski N, Wiesen MHJ et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012; 119: 3276-3284.